RyboDyn Inc, a California-based biotechnology company involved in immunotherapies targeting the dark proteome, announced on Thursday its selection to join Lilly Gateway Labs (LGL) in San Diego, an innovation hub operated with Alexandria Real Estate Equities Inc.

This selection provides RyboDyn with direct access to Eli Lilly and Company's (NYSE:LLY) global scientific and business network -- a critical catalyst as it advances its lead programmes.

RyboDyn has rapidly gained momentum following its discovery of a cryptic proteome -- a previously uncharacterised layer of protein-coding potential derived from overlooked RNA species. Through its proprietary sequencing and AI-driven platform, RyboCypher, the company has uncovered a new class of therapeutic targets that are cancer-specific, abundantly expressed on the cell surface, and absent in healthy tissues. In collaboration with Moffitt Cancer Center, RyboDyn recently demonstrated that several of these 'Dark Targets' are conserved across patients, supporting their potential as the foundation for first-in-class precision immunotherapies.

RyboDyn's LGL residency is part of the Lilly Catalyze360 model, which is a comprehensive approach to empower early-stage biotech startups across all therapeutic areas by providing access to lab space and drug development talent and resources through its three pillars: Lilly Gateway Labs, Lilly ExploR&D, and Lilly Ventures.

With its selection into Lilly Gateway Labs at the One Alexandria Square Megacampus in Torrey Pines, RyboDyn said that it is now accelerating the translation of its dark proteome discoveries into novel therapeutics. It added that it remains focused on building strategic partnerships and advancing its pipeline toward first-in-human studies.